Stock disconnect triggers investor exodus from CStone Pharma
The share price fell nearly 40% in a week after the drugs company was dropped from a scheme allowing mainland investors to trade Hong Kong-listed stocks Key Takeaways: CEO Jason…
Recent Articles
RELATED ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK -
Hengrui Pharma accelerates bid for global brand status
600276.SHG
-
Tsui Wah goes to college as consumers dine out less
1314.HK
-
Goldlion joins stock retreat as brand loses its luster
0533.HK
- Innogen Pharma jostles for a slice of the weight-loss market
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
-
Café de Coral slumps as dark clouds hover over restaurant industry
0341.HK
